Nevro (NVRO) Receiving Somewhat Favorable Media Coverage, Report Finds
Media headlines about Nevro (NYSE:NVRO) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nevro earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.168599106195 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Nevro Corp.: Nevro Receives FDA Approval for Senza II™ Spinal Cord Stimulation System Delivering HF10™ Therapy (twst.com)
- Nevro wins FDA nod for next-gen Senza II SCS (massdevice.com)
- Nevro (NVRO) Announces FDA Approval for Senza II Spinal Cord Stimulation System Delivering HF10 Therapy (streetinsider.com)
- Why Nevro Corp (NYSE: NVRO) stock is going gangbusters today (fxdailyreport.com)
- Nevro Corp.: Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2017 Revenue (twst.com)
Several equities analysts have recently issued reports on NVRO shares. BMO Capital Markets restated a “buy” rating and set a $100.00 price objective on shares of Nevro in a report on Thursday, December 14th. Canaccord Genuity restated a “buy” rating and set a $120.00 price objective on shares of Nevro in a report on Sunday, October 8th. Northland Securities restated a “buy” rating and set a $96.00 price objective on shares of Nevro in a report on Tuesday, November 7th. TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a report on Monday, November 6th. Finally, BidaskClub upgraded shares of Nevro from a “sell” rating to a “hold” rating in a report on Saturday, October 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $99.25.
Nevro (NYSE:NVRO) opened at $78.64 on Thursday. Nevro has a fifty-two week low of $65.00 and a fifty-two week high of $99.63. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81. The firm has a market cap of $2,330.00, a P/E ratio of -54.23 and a beta of -0.83.
Nevro (NYSE:NVRO) last issued its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.02. Nevro had a negative net margin of 14.09% and a negative return on equity of 17.27%. The company had revenue of $82.26 million for the quarter, compared to the consensus estimate of $80.50 million. During the same quarter in the prior year, the company earned ($0.14) EPS. Nevro’s quarterly revenue was up 35.0% on a year-over-year basis. analysts expect that Nevro will post -1.27 earnings per share for the current year.
In related news, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 9.10% of the stock is currently owned by corporate insiders.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with Analyst Ratings Network's FREE daily email newsletter.